PRICE T ROWE ASSOCIATES INC /MD/ - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 160 filers reported holding ALLOGENE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$7,632
-71.2%
2,407,347
-54.8%
0.00%
-75.0%
Q2 2023$26,498
-15.3%
5,331,400
-15.8%
0.00%
-20.0%
Q1 2023$31,273
-16.3%
6,330,304
+6.5%
0.01%
-16.7%
Q4 2022$37,374
-99.9%
5,941,797
+0.6%
0.01%
-40.0%
Q3 2022$63,800,000
+0.7%
5,907,316
+6.3%
0.01%
+25.0%
Q2 2022$63,375,000
+63.0%
5,559,176
+30.3%
0.01%
+100.0%
Q1 2022$38,870,000
-19.9%
4,266,735
+31.2%
0.00%0.0%
Q4 2021$48,513,000
-56.5%
3,251,528
-25.1%
0.00%
-63.6%
Q3 2021$111,512,000
+20.9%
4,338,991
+22.7%
0.01%
+22.2%
Q2 2021$92,198,000
-24.4%
3,535,184
+2.3%
0.01%
-25.0%
Q1 2021$122,023,000
+35.8%
3,456,753
-2.9%
0.01%
+33.3%
Q4 2020$89,849,000
-33.4%
3,559,793
-0.5%
0.01%
-43.8%
Q3 2020$134,914,000
-16.9%
3,577,684
-5.6%
0.02%
-20.0%
Q2 2020$162,321,000
+278.8%
3,790,786
+72.0%
0.02%
+185.7%
Q1 2020$42,856,000
-33.2%
2,204,534
-10.8%
0.01%
-12.5%
Q4 2019$64,184,000
-6.5%
2,470,510
-1.9%
0.01%
-20.0%
Q3 2019$68,646,000
+1.3%
2,518,672
-0.2%
0.01%0.0%
Q2 2019$67,740,000
-4.5%
2,522,906
+0.1%
0.01%0.0%
Q1 2019$70,949,000
+7.7%
2,519,508
+0.3%
0.01%
-9.1%
Q4 2018$65,888,0002,511,9980.01%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$16,381,0009.53%
Wildcat Capital Management, LLC 2,128,370$19,389,0004.96%
TPG GP A, LLC 18,716,306$170,506,0002.11%
Pier Capital, LLC 746,669$6,802,0000.87%
Coastal Bridge Advisors, LLC 401,929$3,662,0000.84%
HARBOR CAPITAL ADVISORS, INC. 92,755$845,0000.40%
Lombard Odier Asset Management (Switzerland) SA 501,219$4,566,0000.36%
Navalign, LLC 74,271$623,0000.26%
PDT Partners, LLC 241,592$2,201,0000.19%
GSA CAPITAL PARTNERS LLP 148,804$1,356,0000.18%
View complete list of ALLOGENE THERAPEUTICS INC shareholders